# Pennant Group share price today (The Pennant Group, Inc., PNTG)

> The Pennant Group, Inc.'s share price has risen faster than its earnings: +66.6% in a year, against +20.0% for earnings per share. PNTG · Healthcare · Medical Care Facilities · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/pntg

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $41.19 (+66.6% in a year)
- P/E: 45.2× (higher than 91% of the last 1 year)
- Revenue (Jun 2026): $298 M (+35.8% on a year ago)
- Profit (Jun 2026): $9.1 M (+28.2% on a year ago)
- Operating margin: 6.2% (+1.4 points on a year ago)
- ROE: 8%, FY25
- ROIC: 5.5%, against a 8.7% cost of capital: −3.2 points

The main question: the share price moved +66.6% in a year while yearly earnings per share moved +20.0%. The difference came from the market paying a higher multiple. ## What is the Pennant Group share price today? The Pennant Group, Inc.'s share price was $41.19 at the close on 3 November 2026. That is 15.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $25 and $42, and at that close it sat 96% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 1 year the share price moved +63% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Pennant Group pay? The Pennant Group, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Pennant Group on? Pennant Group is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Pennant Group profitable? The Pennant Group, Inc. earned $9.1 M of net profit in the Jun 2026 quarter, +28.2% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY25 profit was $29.6 M. Over 4 years profit has grown 82.0% a year on average. That is 3.0% of the quarter's revenue. The same quarter a year earlier earned $7.1 M. For the full year, FY25 profit was $29.6 M (+31.1% on the year before). Why profit moved: revenue changed +35.8% on a year earlier and the margin moved +1.4 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +21.4% and revenue +38.0%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Pennant Group make, and is it growing? The Pennant Group, Inc. reported $298 M of revenue in the Jun 2026 quarter, +35.8% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 21.2% a year on average. The last full year, FY25, came in at $948 M. The last four reported quarters add to $1.1 B. FY25 revenue was $948 M, +36.3% on the year before. Recent pace: the last four quarters grew +38.0% on average, against 21.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +37.9%, against +34.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +20.5%, against +29.3% a year (rolling over). ## How much of every $100 of sales does Pennant Group keep? The Pennant Group, Inc.'s operating margin was 6.2% in the Jun 2026 quarter, 1.4 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 2.2% and 5.4%. The latest quarter is above every full year in that period. Across 5 years it has been between 2.2% and 5.4%, and FY25's 5.4% is the highest of them. Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Pennant Group's profit turning into cash? Over the last 3 years, 184% of The Pennant Group, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $48.3 M of operating cash against $29.6 M of profit. After $22.0 M of spending on assets, $26.3 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Pennant Group's cash go? The Pennant Group, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $50.7 M on assets over the last 3 years. Averaged over those years that is 1.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $50.7 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Pennant Group's P/E ratio, and how does it compare with its own history? The Pennant Group, Inc.'s P/E is 45.2×, near the high end of its own history: higher than 91% of past readings. Its usual P/E (the middle reading) is 37.5×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +20.0% while the price moved +66.6%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Pennant Group business getting better or worse? The Pennant Group, Inc.'s business is giving mixed signals. Growth has been steadily positive, but ROCE at 8.3% is below the 15% level needed to call it steady growth. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Pennant Group earn on its capital? The Pennant Group, Inc. earned a ROE of 8% in FY25. That is up from a low of 2% in FY21. Its return on capital used (ROIC) is 3.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 3.1% net margin and 0.98× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 3.1% net margin × 0.98× asset turnover × 2.59× leverage (assets divided by equity) ≈ 7.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 5.5% − 8.7% = −3.2 percentage points. The 8.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Pennant Group have too much debt? The Pennant Group, Inc. has total debt of $496 M against shareholder equity of $404 M as of Jun 2026, so its debt is 1.23× its equity. Year by year, that ratio went from 3.11 in FY21 to 1.23 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Pennant Group shareholding pattern? 3.5% of The Pennant Group, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Pennant Group from balance-sheet trouble? For The Pennant Group, Inc., the Z-score is 2.38. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.38 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Pennant Group rank in its industry? 43.9 out of 100, rank 21 of 30 in Medical Care Facilities, with 81% of the evidence available. The Pennant Group, Inc. scores 43.9 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 21. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 20.7 + 8.3 + 5.7 + 9.2 = 43.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Pennant Group compared with? Pennant Group ranks 21 of 30 Medical Care Facilities companies on the 4-Factor Sector Score, with 43.9 out of 100. 1. [Concentra Group Holdings Parent, Inc.](https://www.sectoralpha.in/us/stocks/con) CON · leader · Most evidence points up · 81% evidence 71.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 14% · Profit 32.6% · Operating margin change 2.3 points · 83% evidence Capital efficiency 16.6/25 · ROCE 14.5% · Operating margin 19.3% · 76% evidence Valuation 13.0/20 · P/E 19.5× · PEG 0.65 · 65% evidence Relative strength 17.3/20 · Lead over its industry 18.3% · Lead over S&P 500 41.8% · 1 year 107.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.4 + 16.6 + 13 + 17.3 = 71.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Tenet Healthcare Corporation](https://www.sectoralpha.in/us/stocks/thc) THC · losing its lead · Evidence leans up · 81% evidence 64.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 5.4% · Profit 32.4% · Operating margin change 2.1 points · 83% evidence Capital efficiency 17.1/25 · ROCE 15% · Operating margin 18.2% · 76% evidence Valuation 15.3/20 · P/E 7.2× · PEG 0.35 · 65% evidence Relative strength 11.1/20 · Lead over its industry -3.8% · Lead over S&P 500 16.9% · 1 year 29.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21 + 17.1 + 15.3 + 11.1 = 64.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [AMN Healthcare Services, Inc.](https://www.sectoralpha.in/us/stocks/amn) AMN · breaking out · Evidence leans up · 64% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 23.9% · Profit n/a · Operating margin change 3.4 points · 62% evidence Capital efficiency 9.1/25 · ROCE 10.1% · Operating margin 4% · 76% evidence Valuation 10.4/20 · P/E 12× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.8% · Lead over S&P 500 63.5% · 1 year 153.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.3 + 9.1 + 10.4 + 19.6 = 64.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Pediatrix Medical Group, Inc.](https://www.sectoralpha.in/us/stocks/md) MD · turning · Evidence leans up · 81% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 0.6% · Profit 61.5% · Operating margin change -0.2 points · 83% evidence Capital efficiency 14.6/25 · ROCE 14.8% · Operating margin 13.4% · 76% evidence Valuation 13.1/20 · P/E 11.6× · PEG 0.8 · 65% evidence Relative strength 15.2/20 · Lead over its industry 1.2% · Lead over S&P 500 23% · 1 year 39.5% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.4 + 14.6 + 13.1 + 15.2 = 62.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Healthcare Services Group, Inc.](https://www.sectoralpha.in/us/stocks/hcsg) HCSG · turning · Evidence leans up · 85% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 4% · Profit 100% · Operating margin change -3.2 points · 95% evidence Capital efficiency 14.5/25 · ROCE 17.7% · Operating margin 6.7% · 76% evidence Valuation 14.4/20 · P/E 13.4× · PEG 0.43 · 65% evidence Relative strength 12.6/20 · Lead over its industry -4.8% · Lead over S&P 500 15.9% · 1 year 48.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 14.4 + 12.6 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Encompass Health Corporation](https://www.sectoralpha.in/us/stocks/ehc) EHC · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.5% · Profit 20.2% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.1/25 · ROCE 17% · Operating margin 18.1% · 76% evidence Valuation 12.4/20 · P/E 16.2× · PEG 0.8 · 65% evidence Relative strength 12.9/20 · Lead over its industry -4.8% · Lead over S&P 500 16.2% · 1 year 16.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 18.1 + 12.4 + 12.9 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) NUTX · leader · Evidence leans up · 64% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 6.8% · Profit 100% · Operating margin change 44 points · 62% evidence Capital efficiency 18.6/25 · ROCE 56.8% · Operating margin 57.8% · 76% evidence Valuation 10.9/20 · P/E 6.5× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -5.5% · Lead over S&P 500 14.2% · 1 year 56.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.5 + 18.6 + 10.9 + 8.3 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aveanna Healthcare Holdings Inc.](https://www.sectoralpha.in/us/stocks/avah) AVAH · leader · Too little evidence to rank firmly · 58% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.3/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 45% evidence Capital efficiency 15.3/25 · ROCE 17.7% · Operating margin 12.6% · 76% evidence Valuation 10.7/20 · P/E 7.2× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 14.4% · Lead over S&P 500 37.9% · 1 year 51.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 15.3 + 15.3 + 10.7 + 18.2 = 59.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Addus HomeCare Corporation](https://www.sectoralpha.in/us/stocks/adus) ADUS · turning · Evidence leans up · 81% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 15.9% · Profit 27.7% · Operating margin change 0.3 points · 83% evidence Capital efficiency 12.9/25 · ROCE 11.4% · Operating margin 9.7% · 76% evidence Valuation 13.0/20 · P/E 17.4× · PEG 0.67 · 65% evidence Relative strength 10.7/20 · Lead over its industry -8.5% · Lead over S&P 500 11.9% · 1 year 11.9% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21 + 12.9 + 13 + 10.7 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [HCA Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/hca) HCA · breaking out · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 7.3% · Profit 14.6% · Operating margin change -0.7 points · 83% evidence Capital efficiency 19.9/25 · ROCE 26.3% · Operating margin 15.2% · 76% evidence Valuation 14.3/20 · P/E 12.6× · PEG 0.49 · 65% evidence Relative strength 7.2/20 · Lead over its industry -21.2% · Lead over S&P 500 -2.7% · 1 year -2.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 19.9 + 14.3 + 7.2 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) UHS · losing its lead · Evidence leans up · 81% evidence 56.3 out of 100 Growth Capital Valuation Relative
12. [LifeStance Health Group, Inc.](https://www.sectoralpha.in/us/stocks/lfst) LFST · turning · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative
13. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) NHC · quiet · Evidence leans up · 81% evidence 54.0 out of 100 Growth Capital Valuation Relative
14. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) PACS · quiet · Evidence leans up · 71% evidence 53.7 out of 100 Growth Capital Valuation Relative
15. [Fresenius Medical Care AG](https://www.sectoralpha.in/us/stocks/fms) FMS · basing · Evidence leans up · 81% evidence 50.7 out of 100 Growth Capital Valuation Relative
16. [Chemed Corporation](https://www.sectoralpha.in/us/stocks/che) CHE · quiet · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative
17. [Guardian Pharmacy Services, Inc.](https://www.sectoralpha.in/us/stocks/grdn) GRDN · quiet · Evidence leans down · 64% evidence 49.3 out of 100 Growth Capital Valuation Relative
18. [Surgery Partners, Inc.](https://www.sectoralpha.in/us/stocks/sgry) SGRY · turning · Evidence leans down · 64% evidence 48.8 out of 100 Growth Capital Valuation Relative
19. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) DVA · turning · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
20. [Astrana Health, Inc.](https://www.sectoralpha.in/us/stocks/asth) ASTH · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
21. The Pennant Group, Inc. this page PNTG · turning · Evidence leans down · 81% evidence 43.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 37.6% · Profit 22.2% · Operating margin change 1.4 points · 83% evidence Capital efficiency 8.3/25 · ROCE 7.2% · Operating margin 6.2% · 76% evidence Valuation 5.7/20 · P/E 39.7× · PEG 2.38 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.8% · Lead over S&P 500 15.2% · 1 year 61.3% · 100% evidence · 7 of 12 weeks ahead Exact sum: 20.7 + 8.3 + 5.7 + 9.2 = 43.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 22. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) ENSG · turning · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
23. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) AGL · quiet · Evidence leans down · 64% evidence 41.2 out of 100 Growth Capital Valuation Relative
24. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) OPCH · breaking out · Evidence leans down · 81% evidence 41.0 out of 100 Growth Capital Valuation Relative
25. [Acadia Healthcare Company, Inc.](https://www.sectoralpha.in/us/stocks/achc) ACHC · quiet · Evidence leans down · 71% evidence 37.5 out of 100 Growth Capital Valuation Relative
26. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) USPH · leader · Evidence leans down · 81% evidence 36.3 out of 100 Growth Capital Valuation Relative
27. [Sonida Senior Living, Inc.](https://www.sectoralpha.in/us/stocks/snda) SNDA · basing · Evidence leans down · 64% evidence 36.2 out of 100 Growth Capital Valuation Relative
28. [Ardent Health, Inc.](https://www.sectoralpha.in/us/stocks/ardt) ARDT · losing its lead · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Brookdale Senior Living Inc.](https://www.sectoralpha.in/us/stocks/bkd) BKD · quiet · Most evidence points down · 64% evidence 32.8 out of 100 Growth Capital Valuation Relative
30. [Select Medical Holdings Corporation](https://www.sectoralpha.in/us/stocks/sem) SEM · Too little evidence to rank firmly · 36% evidence 50.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Care Facilities](https://www.sectoralpha.in/us/sectors/medical-care-facilities), all 30 compared on one page. ## Which companies are close to Pennant Group in size? Pennant Group is the 28th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Ardent Health, Inc., Sonida Senior Living, Inc. and agilon health, inc. Just below it: U.S. Physical Therapy, Inc., Nutex Health Inc. and InnovAge Holding Corp. ### Medical Care Facilities companies close in size

1. [Ardent Health, Inc.](https://www.sectoralpha.in/us/stocks/ardt) $1.7 billion
2. [Sonida Senior Living, Inc.](https://www.sectoralpha.in/us/stocks/snda) $1.6 billion
3. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) $1.5 billion
4. The Pennant Group, Inc. $1.4 billion
5. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) $1.3 billion
6. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) $1.2 billion
7. [InnovAge Holding Corp.](https://www.sectoralpha.in/us/stocks/innv) $1.2 billion

[All 38 Medical Care Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/medical-care-facilities#all-companies)

### Companies close in size in other industries

1. [Permian Basin Royalty Trust](https://www.sectoralpha.in/us/stocks/pbt) $1.4 billion · Oil & Gas Midstream
2. [Empire State Realty Trust, Inc.](https://www.sectoralpha.in/us/stocks/esrt) $1.4 billion · REIT - Diversified
3. The Pennant Group, Inc. $1.4 billion
4. [Westamerica Bancorporation](https://www.sectoralpha.in/us/stocks/wabc) $1.4 billion · Banks - Regional
5. [Atlanticus Holdings Corporation](https://www.sectoralpha.in/us/stocks/atlc) $1.4 billion · Credit Services

## What else do people ask about Pennant Group? ### What were Pennant Group's latest quarterly results? The Pennant Group, Inc. reported revenue of $298 M and net profit of $9.1 M for the Jun 2026 quarter. Revenue rose 35.8% and profit rose 28.2% compared with a year earlier. Earnings per share were $0.25. The operating margin was 6.2%, 1.4 percentage points higher than a year earlier (as of 3 November 2026). ### What is Pennant Group's market cap? The Pennant Group, Inc.'s market capitalisation is $1.4 B at a stock price of $41.19. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Pennant Group performing? The Pennant Group, Inc.'s latest readings are below. In its latest quarter, revenue rose 35.8% and profit rose 28.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Pennant Group's stock price go up? This page does not forecast The Pennant Group, Inc.'s stock price. What it shows instead: the stock price is $41.19. Its P/E of 45.2× is higher than 91% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Pennant Group in its business cycle? The Pennant Group, Inc.'s FY25 operating margin was 5.4%, against a 5-year range of 2.2% to 5.4%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 6.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Pennant Group story? The main question: the share price moved +66.6% in a year while yearly earnings per share moved +20.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Pennant Group a stock worth studying right now? What the numbers show: The Pennant Group, Inc.'s share price has risen faster than its earnings: +66.6% in a year, against +20.0% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.